Literature DB >> 26774223

Acoustic Cluster Therapy (ACT) - pre-clinical proof of principle for local drug delivery and enhanced uptake.

Annemieke van Wamel1, Andrew Healey2, Per Christian Sontum2, Svein Kvåle2, Nigel Bush3, Jeff Bamber3, Catharina de Lange Davies4.   

Abstract

Proof of principle for local drug delivery with Acoustic Cluster Therapy (ACT) was demonstrated in a human prostate adenocarcinoma growing in athymic mice, using near infrared (NIR) dyes as model molecules. A dispersion of negatively charged microbubble/positively charged microdroplet clusters are injected i.v., activated within the target pathology by diagnostic ultrasound (US), undergo an ensuing liquid-to-gas phase shift and transiently deposit 20-30μm large bubbles in the microvasculature, occluding blood flow for ~5-10min. Further application of low frequency US induces biomechanical effects that increase the vascular permeability, leading to a locally enhanced extravasation of components from the vascular compartment (e.g., released or co-administered drugs). Results demonstrated deposition of activated bubbles in tumor vasculature. Following ACT treatment, a significant and tumor specific increase in the uptake of a co-administered macromolecular NIR dye was shown. In addition, ACT compound loaded with a lipophilic NIR dye to the microdroplet component was shown to facilitate local release and tumor specific uptake. Whereas the mechanisms behind the observed increased and tumor specific uptake are not fully elucidated, it is demonstrated that the ACT concept can be applied as a versatile technique for targeted drug delivery.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACT; Acoustic cluster therapy; Local drug delivery; PC-3 prostate adenocarcinoma; Pre-clinical

Mesh:

Substances:

Year:  2016        PMID: 26774223     DOI: 10.1016/j.jconrel.2016.01.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes.

Authors:  Feng-Ying Huang; Jing Lei; Yan Sun; Fei Yan; Bin Chen; Liming Zhang; Zhuoxuan Lu; Rong Cao; Ying-Ying Lin; Cai-Chun Wang; Guang-Hong Tan
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

2.  Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.

Authors:  Hanan Abumanhal-Masarweh; Lilach Koren; Assaf Zinger; Zvi Yaari; Nitzan Krinsky; Galoz Kaneti; Nitsan Dahan; Yael Lupu-Haber; Edith Suss-Toby; Esther Weiss-Messer; Michal Schlesinger-Laufer; Janna Shainsky-Roitman; Avi Schroeder
Journal:  J Control Release       Date:  2019-01-05       Impact factor: 9.776

3.  Efficient Enhancement of Blood-Brain Barrier Permeability Using Acoustic Cluster Therapy (ACT).

Authors:  Andreas K O Åslund; Sofie Snipstad; Andrew Healey; Svein Kvåle; Sverre H Torp; Per C Sontum; Catharina de Lange Davies; Annemieke van Wamel
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

4.  Safety assessment in rats and dogs of Acoustic Cluster Therapy, a novel concept for ultrasound mediated, targeted drug delivery.

Authors:  Oddvar Myhre; Marie Bjørgan; Derek Grant; Svein-Olaf Hustvedt; Per C Sontum; Hubert Dirven
Journal:  Pharmacol Res Perspect       Date:  2016-11-17

5.  Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice.

Authors:  Nigel Bush; Andrew Healey; Anant Shah; Gary Box; Vladimir Kirkin; Spiros Kotopoulis; Svein Kvåle; Per Christian Sontum; Jeffrey Bamber
Journal:  Front Pharmacol       Date:  2019-11-19       Impact factor: 5.810

6.  Theranostic Attributes of Acoustic Cluster Therapy and Its Use for Enhancing the Effectiveness of Liposomal Doxorubicin Treatment of Human Triple Negative Breast Cancer in Mice.

Authors:  Nigel Bush; Andrew Healey; Anant Shah; Gary Box; Vladimir Kirkin; Sue Eccles; Per Christian Sontum; Spiros Kotopoulis; Svein Kvåle; Annemieke van Wamel; Catharina de Lange Davies; Jeffrey Bamber
Journal:  Front Pharmacol       Date:  2020-02-20       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.